


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

CHANGE OF PRESIDENT AND APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Kontafarma China Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that:-

1. Mr. Wang Limin (王利民先生) (“**Mr. Wang**”), an executive Director and the chairman of the Board, has tendered his resignation as the president of the Group (the “**President**”) due to internal adjustment of work arrangement but he will continue to serve as an executive Director and the chairman of the Board as well as the chairman of each of the executive committee of the Company (the “**Executive Committee**”), the nomination committee of the Company, the share dealing committee of the Company (the “**Share Dealing Committee**”) and the investment committee of the Company; and
2. Mr. Li Qingshan (李青山先生) (“**Mr. Li**”) has been appointed as an executive Director and the President as well as a member of each of the Executive Committee and the Share Dealing Committee,

all with effect from 17 August 2026.

Mr. Wang has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The biographical details of Mr. Li are set out as follows:

Mr. Li Qingshan, aged 46, has been appointed as the Communist Party Committee member of Shenzhen Warranty Asset Management Co., Ltd.* (深圳市華融泰資產管理有限公司) (“**Shenzhen Warranty**”) since June 2024, and deputy general manager of Shenzhen Warranty from June 2024 to July 2026. Mr. Li served as a non-independent director of Shenzhen Huakong Seg Co., Ltd. (深圳華控賽格股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 000068) from October 2024 to August 2026. Mr. Li also served as the chairman of the board and a director of SPF (Beijing) Biotechnology Co., Ltd.* (斯貝福(北京)生物技術有限公司) from June 2024 to June 2026, the chairman of the board of Shaanxi Unisplendour Life Care Pharmaceutical Co., Ltd.* (陝西紫光辰濟藥業有限公司) from June 2024 to March 2026, and the chairman of the board and a director of Tongfang Pharmaceutical (Beijing) Co., Ltd.* (桐方藥業(北京)有限公司) (formerly known as Tongfang Pharmaceutical Group Co., Ltd.* (同方藥業集團有限公司)) from October 2025 to April 2026.

Mr. Li obtained a postgraduate’s degree at Shanxi Provincial Committee Party School of C.P.C* (中共山西省委黨校) (currently known as Shanxi Provincial Committee Party School of C.P.C (Shanxi Administrative College)* (中共山西省委黨校(山西行政學院)) in July 2023.

Mr. Li entered into a service contract with the Company as an executive Director and the President on 17 August 2026. There was no fixed term as to his appointment as an executive Director subject to the requirements for retirement by rotation and re-election in accordance with the memorandum and articles of association of the Company. Pursuant to the service contract, Mr. Li agrees to waive his entitlement to any Director’s fee from the Company as an executive Director.

Save as disclosed above, as at the date of this announcement, Mr. Li (i) does not hold any other positions with the Company or its subsidiaries; (ii) does not have any other major appointments and professional qualifications; (iii) does not have any relationship with any other Directors, senior management, substantial Shareholders (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) or controlling Shareholders (as defined under the Listing Rules) of the Company; (iv) is not interested in the shares of the Company as defined in Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) does not hold any directorships in any listed public companies in Hong Kong or overseas in the past three years.

Save for the information set out above, there is no other information which is discloseable pursuant to any requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters that need to be brought to the attention of the Shareholders in relation to the appointment of Mr. Li.

The Board would like to express its warm welcome to Mr. Li for joining the Board.

By order of the Board of
Kontafarma China Holdings Limited
Wang Limin
Chairman

Hong Kong, 17 August 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Limin (Chairman), Mr. Li Qingshan (President), Mr. Ge Shouwen (Vice President), and Ms. Guo Zixiu (Financial Controller); and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.

** For identification purposes only*